Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
RVMD Today - Aug 10: Stays Steady Amid News
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
So, what went down? Well, RVMD had a pretty steady day. It didn’t get smoked, but it didn’t exactly shoot for the stars either. Just a slow and steady vibe. The trading volume was right around the average, so nothing too wild happening there.
Now, why did it play out this way? Some interesting stuff came to light. TD Cowen kept the stock rating at a solid Buy, which is a thumbs-up for RVMD. That probably gave some investors a little boost of confidence. Also, BeOne snagged exclusive rights to four cancer medicines in certain Asian markets. That’s a big deal, right? More markets mean more potential sales. Plus, there’s been a growing demand for Daraxonrasib, one of their treatments. People are talking about it, and it sounds like that’s been helping RVMD bounce back a bit after some rough patches.
Oh, and get this: Assenagon Asset Management picked up over 200,000 shares of RVMD. Major institutional buying can be a good sign, showing that some big players are betting on the stock.
Now, looking ahead, Revolution Medicines is still in the game with Daraxonrasib and its pipeline. So, there’s definitely stuff cooking.
Alright, that’s a wrap for today! Just remember, this is all for fun and info, not financial advice. Catch you later!
adbl_web_anon_alc_button_suppression_t1
No reviews yet